Tags

Type your tag names separated by a space and hit enter

Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
Ther Adv Respir Dis. 2015 Apr; 9(2):49-55.TA

Abstract

The international guidelines on chronic obstructive pulmonary disease (COPD) recommend inhaled bronchodilators for maintenance treatment of the disease. These drugs include β2-agonists and muscarinic antagonists, which are both available as short-acting agents (to be used as needed for dyspnea) and long-acting agents. To the latter belong salmeterol and formoterol (long-acting β2-agonists) and indacaterol, vilanterol and olodaterol (very long-acting β2-agonist) as β2-agonists, and tiotropium, aclidinium and glycopyrronium bromide as long-acting muscarinic antagonists. The efficacy and safety of indacaterol and glycopyrronium as monotherapies has been demonstrated in several controlled trials. However, in some patients with moderate-to-severe COPD, symptoms are poorly controlled by bronchodilator monotherapy; in these cases the addition of a second bronchodilator from a different pharmacological class may be beneficial. Here we review the evidence from published randomized trials concerning the efficacy and safety of the once-daily fixed-dose dual bronchodilator combining indacaterol and glycopyrronium.

Authors+Show Affiliations

Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy.Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy.Pulmonary Rehabilitation, ICP Hospital, Milan, Italy.Pulmonary Rehabilitation, ICP Hospital, Milan, Italy.Pulmonary Rehabilitation, ICP Hospital, Milan, Italy cristoforo.incorvaia@gmail.com.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

25691493

Citation

Ridolo, Erminia, et al. "Combination Therapy With Indacaterol and Glycopyrronium Bromide in the Management of COPD: an Update On the Evidence for Efficacy and Safety." Therapeutic Advances in Respiratory Disease, vol. 9, no. 2, 2015, pp. 49-55.
Ridolo E, Montagni M, Riario-Sforza GG, et al. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety. Ther Adv Respir Dis. 2015;9(2):49-55.
Ridolo, E., Montagni, M., Riario-Sforza, G. G., Baroni, M., & Incorvaia, C. (2015). Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety. Therapeutic Advances in Respiratory Disease, 9(2), 49-55. https://doi.org/10.1177/1753465815572065
Ridolo E, et al. Combination Therapy With Indacaterol and Glycopyrronium Bromide in the Management of COPD: an Update On the Evidence for Efficacy and Safety. Ther Adv Respir Dis. 2015;9(2):49-55. PubMed PMID: 25691493.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety. AU - Ridolo,Erminia, AU - Montagni,Marcello, AU - Riario-Sforza,Gian Galeazzo, AU - Baroni,Marco, AU - Incorvaia,Cristoforo, Y1 - 2015/02/17/ PY - 2015/2/19/entrez PY - 2015/2/19/pubmed PY - 2015/12/25/medline KW - chronic obstructive pulmonary disease KW - glycopyrronium KW - indacaterol KW - muscarinic antagonists KW - treatment guidelines KW - β2-agonist SP - 49 EP - 55 JF - Therapeutic advances in respiratory disease JO - Ther Adv Respir Dis VL - 9 IS - 2 N2 - The international guidelines on chronic obstructive pulmonary disease (COPD) recommend inhaled bronchodilators for maintenance treatment of the disease. These drugs include β2-agonists and muscarinic antagonists, which are both available as short-acting agents (to be used as needed for dyspnea) and long-acting agents. To the latter belong salmeterol and formoterol (long-acting β2-agonists) and indacaterol, vilanterol and olodaterol (very long-acting β2-agonist) as β2-agonists, and tiotropium, aclidinium and glycopyrronium bromide as long-acting muscarinic antagonists. The efficacy and safety of indacaterol and glycopyrronium as monotherapies has been demonstrated in several controlled trials. However, in some patients with moderate-to-severe COPD, symptoms are poorly controlled by bronchodilator monotherapy; in these cases the addition of a second bronchodilator from a different pharmacological class may be beneficial. Here we review the evidence from published randomized trials concerning the efficacy and safety of the once-daily fixed-dose dual bronchodilator combining indacaterol and glycopyrronium. SN - 1753-4666 UR - https://www.unboundmedicine.com/medline/citation/25691493/Combination_therapy_with_indacaterol_and_glycopyrronium_bromide_in_the_management_of_COPD:_an_update_on_the_evidence_for_efficacy_and_safety_ L2 - http://journals.sagepub.com/doi/full/10.1177/1753465815572065?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -